GlassScriptPhysician profile
Brian Anthony Hunter
NPI 1528264793
$3,563.59
in general payments reported to CMS, 2019-2025
21 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $253 · 2021: $321 · 2022: $483 · 2023: $658 · 2024: $1,060 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887 · Honoraria: $51.18 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.59 |
| Honoraria | $51.18 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $759.45 | 2019-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $559.76 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $448.27 | 2019-2024 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $385.19 | 2019-2025 | Argos, Tryptyr, Simbrinza |
| Carl Zeiss Meditec, INC. | $231.58 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $184.71 | 2019-2022 | |
| Abbvie INC. | $174.58 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $114.73 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $90.89 | 2024 | Veritas Vision System |
| Aerie Pharmaceuticals, INC. | $87.61 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $71.93 | 2022-2023 | Miebo, Prolensa, Vyzulta |
| Amgen INC. | $71.83 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $71.71 | 2024 | Xdemvy |
| Allergan, INC. | $71.44 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.00 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $64.63 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $23.65 | 2024 | Omidria |
| Harrow Eye, LLC | $23.43 | 2024 | Natacyn, Tobradex St, Verkazia |
| Kala Pharmaceuticals, INC. | $20.91 | 2019 | |
| Horizon Therapeutics Plc | $18.62 | 2021 | |
| Oyster Point Pharma, INC. | $17.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.